ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1942

Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags

Shima Yasin1, T. Shawn Sato2, Emma Leisinger2, Aleksander Lenert2, Yongdong (Dan) Zhao3 and Polly Ferguson1, 1University of Iowa Carver College of Medicine, Iowa City, IA, 2University of Iowa, Iowa City, IA, 3University of Washington, Redmond, WA

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, Back pain, Miscellaneous Rheumatic and Inflammatory Diseases, practice guidelines, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Pediatric Rheumatology – Clinical Poster III: Other

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is a female predominant autoinflammatory bone disease. The average age at disease onset is 9-10 years. The majority have favorable long-term outcomes. With wide utilization of whole-body MRI (WBMRI), increased reports of spine disease (SD) with variable degree of severity and vertebral plana were highlighted. SD is now considered a classic finding in CRMO, its incidence is reported at 10-35% in CRMO. To date, risk factors for SD in CRMO are unknown. SD can result in damaging outcomes such as vertebral fractures and deformities. Leveraging our large cohort, we aimed at characterizing clinical and radiological features of SD in CRMO, and identifying candidate clinical risk factors and red flags for SD in CRMO patients.

Methods: This study was approved by Institutional Review Board. Using retrospective chart review we identified cases of any degree SD in CRMO based on MRI findings (N:36), and matched those with 36 controls (CRMO patients without SD) using current age in case-control design. Clinical data was abstracted from medical records. We used Fischer exact and T.test for comparisons.

Results: In our cohort, patients with SD (summarized in table 1) were mostly Caucasian (83%), and two-thirds from out of state (second opinion). Despite female predominance (67%), the proportion of male with SD in the whole study (cases and control) was higher than female proportion (57% (12/21) vs 47% (24/51)). The majority (92%) had thoracic vertebra involvement, and 20% had vertebra plana. 42% had associated autoimmune disease (AID). Mean age at CRMO onset was 9.3 ± 2.9 years, and time to diagnosis was 6.8±6.2 months. Notably presenting at slightly older age, SD cases were not significantly different from controls in age at onset (p:0.09) or time to diagnosis (p 0.89) (Figure 1).

In SD, 47% of patients did not have back pain at CRMO onset and only 69% complained of back pain just prior to SD diagnosis. Most alarming, 31% (11/36) were asymptomatic with SD diagnosed incidentally on WBMRI. Pain at night and sleep disturbances were present in 67%, with significant difference compared to control (OR 3.5, p: 0.018) (Figure 2-A). Similarly, presence of back pain was a significant risk factor for SD (OR 39, p < 0.0001) (Figure 2-B). When compared to controls, SD patients did not have significant difference in presence of fever (p 0.15), arthritis (p 0.39), AID (p 0.21), or family history of AID (p 0.3). 33% were on NSAIDs when SD developed, of those 89% reported pain and poor CRMO control despite NSAIDs.

Conclusion: SD in CRMO is not as rare as previously suggested. Patients with SD present at slightly older age, and males might be affected at higher proportion. Nearly half of patients with SD did not report back pain at onset of CRMO symptoms and one-third had no back pain despite active lesions on WBMRI at the time of SD diagnosis. Utilization of universal WBMRI for every child with suspected or diagnosed CRMO initially and at subsequent follow up is crucial. Early and prompt targeted therapy for SD is critical in preventing long term sequalae such as vertebra plana and deformities. Complains of back pain, pain at night, and sleep disturbances are risk factors and red flags for SD and should prompt immediate screening.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Yasin, None; T. Sato, None; E. Leisinger, None; A. Lenert, None; Y. Zhao, None; P. Ferguson, None.

To cite this abstract in AMA style:

Yasin S, Sato T, Leisinger E, Lenert A, Zhao Y, Ferguson P. Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/maybe-silent-spine-disease-in-chronic-recurrent-multifocal-osteomyelitis-clinical-features-risk-factors-and-red-flags/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/maybe-silent-spine-disease-in-chronic-recurrent-multifocal-osteomyelitis-clinical-features-risk-factors-and-red-flags/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology